University Hospital Zürich Skin Cancer Center, Zürich, Switzerland
Reinhard Dummer , Axel Hauschild , Mario Santinami , Victoria Atkinson , Mario Mandalà , Vanna Chiarion-Sileni , James M. G. Larkin , Marta Nyakas , Caroline Dutriaux , Andrew Mark Haydon , Caroline Robert , Dirk Schadendorf , Paola Aimone , Bijoyesh Mookerjee , Catarina D. Campbell , James Garrett , Jan C. Brase , Richard Kefford , John M. Kirkwood , Georgina V. Long
Background: In the COMBI-AD trial, adjuvant D + T resulted in a significant relapse-free survival benefit (HR, 0.47 [95% CI, 0.39-0.58]; P< .001) vs pbo in pts with resected stage III BRAF V600E/K–mutant melanoma. At a median follow-up of 2.8 y, 37% of pts in the D + T arm and 57% in the pbo arm had relapsed. Resistance mechanisms are largely unknown in the adjuvant setting. We report mutational and immune gene expression profiling at relapse in COMBI-AD. Methods: COMBI-AD (NCT01682083) randomized pts with resected stage III BRAF V600E/K–mutant melanoma to receive D + T or pbo. DNA and RNA were extracted from the same relapse sample. Mutational landscape and immune gene expression signature were examined by sequencing 570 genes (mean depth ≈ 500×) and gene expression profiling using a customized NanoString panel. Plasma samples were subjected to ctDNA profiling (73 genes). Results: At relapse, 66 tissue samples (D + T, n = 24 [n = 4 relapsed on treatment]; pbo, n = 42) were collected (20 distant, 43 local/regional, 3 secondary primary melanoma). Paired baseline samples were available in most cases (n = 57). A BRAF V600E/K mutation was detected in all relapse samples except in 1 secondary primary melanoma. The genomic landscape was as expected for melanoma: the most common non–BRAF V600 genetic aberrations were CDKN2A (38%), CDKN2B (24%), PTEN (23%), TP53 (18%), and ARID2 (14%), and median tumor mutation burden (TMB) was ≈ 10 SNVs/Mb. No substantial differences in mutation frequency, TMB, or BRAF copy number were noted in relapse vs baseline samples or between treatment arms. Putative genetic resistance mechanisms in the MAPK (eg, MAP2K1, NRAS mutations) and non-MAPK (eg, PI3K pathway mutations) pathways were found in a small subset of relapse samples from pts treated with D + T. No significant differences in T-cell–specific/immune gene expression signatures were observed between arms. Conclusions: Although mutations in MAPK and non-MAPK pathways were found in a few relapse samples, no uniform adaptations were observed, suggesting that resistance to adjuvant D + T is caused by various genetic/epigenetic mechanisms. Clinical trial information: NCT01682083
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Amit Mahipal
2022 ASCO Annual Meeting
First Author: Nichol Miller
2019 ASCO Annual Meeting
First Author: Dirk Schadendorf
2022 ASCO Annual Meeting
First Author: Dirk Schadendorf